Why DNA Methylation Biomarkers are Ideal Targets for Diagnostics
DNA Methylation and Cancer
There is a known correlation between DNA methylation and aberrant gene regulation involved in the initiation and progression of cancer, as well as response to treatment.
DNA Methylation occurs early in cancer and continues to change as disease progresses and during treatment.
DNA methylation changes often occur at an early stage in cancer and other disease, which makes DNA methylation biomarkers ideal targets for the early detection of disease. Methylation levels continue to change as disease progresses and can also be used to stage and/or subtype disease. DNA methylation can impact patient response to certain drugs, and changes in DNA methylation can cause acquired drug resistance during treatment.
DNA Methylation is a Stable Biomarker.
Methylated DNA is a stable biomarker that is amenable to reliable analysis of patient samples that do not have special handling requirements. Unlike many other test formats, DNA methylation is easily detected in retrospective archived samples, and in FFPE clinical samples, and is more stable than mRNA.
DNA Methylation Enables Patient Stratification before Treatment.
DNA Methylation is often involved in therapeutic drug resistance and sensitivity that are common roadblocks encountered in current cancer treatment regimens. Consequently, DNA methylation biomarkers are particularly well suited to developing appropriate patient stratification prior to drug treatment, and monitoring patient responses during treatment.